Austin, Texas, January 12, 2026
Natera, Inc. has announced strong preliminary financial results, showcasing substantial growth in both revenues and tests processed, particularly in their oncology testing services. The fourth quarter reveled in $660 million in revenue, and the full year achieved $2.3 billion, largely due to the rising demand for personalized medicine. CEO Steve Chapman expressed confidence in continuing this positive momentum. The company will present these results at the upcoming J.P. Morgan Healthcare Conference.
Austin, Texas – Natera, Inc. (NASDAQ: NTRA), a renowned player in cell-free DNA and precision medicine, recently shared impressive preliminary financial results for the fourth quarter and full year ended December 31, 2025. The company’s remarkable achievements can be attributed largely to the rapid growth of its Signatera™ oncology testing services, which has seen increasing demand as personalized medicine continues to gain traction.
The financial outlook for Natera is a testament to the outstanding entrepreneurial spirit prevalent in Austin. Navigating through the challenges of an evolving healthcare landscape, companies like Natera demonstrate resilience and innovation, contributing significantly to the local economy. With reduced regulatory burdens, there is potential for even more agile responses to market demands, fostering an environment where businesses can thrive.
Fourth Quarter 2025 Highlights
- Total Revenues: Approximately $660 million, a 39% increase from $476 million in the same period of 2024.
- Oncology Tests Processed: About 233,300 tests, marking a 55% year-over-year growth.
- Clinical Minimal Residual Disease (MRD) Tests: Approximately 225,300 tests, achieving record sequential growth despite fewer sample days.
- Total Tests Processed: Around 923,600 tests, up 17% from 792,800 tests in Q4 2024.
- Cash Inflows: Approximately $30 million, compared to $46 million in Q4 2024.
Full Year 2025 Highlights
- Total Revenues: Approximately $2.3 billion, a 35% increase from $1.7 billion in 2024.
- Total Tests Processed: Approximately 3,525,500 tests, up 15% from 3,064,600 tests in 2024.
- Oncology Tests Processed: About 800,800 tests, including 769,700 clinical MRD tests, a 52% increase from 528,200 oncology tests in 2024.
- Cash Inflows: Exceeded $100 million for the full year.
CEO’s Statement
Steve Chapman, CEO of Natera, emphasized that 2025 marked a record year for oncology, organ health, and women’s health. The company experienced significant growth in volume, revenue, and gross margins. He expressed optimism about Natera’s ability to sustain this momentum throughout 2026 and beyond.
Upcoming Presentation
Natera is poised to present these financial results at the upcoming 44th Annual J.P. Morgan Healthcare Conference, scheduled for January 13, 2026, at 4:30 pm PT. Attendees can expect further insights and business updates during this important gathering.
About Natera
Natera stands at the forefront of cell-free DNA and precision medicine, focusing on oncology, women’s health, and organ health. The company’s mission is to integrate personalized genetic testing and diagnostics into standard medical care, aiming to enhance healthcare outcomes through timely and targeted interventions. Natera’s credibility is backed by over 350 peer-reviewed publications that affirm the effectiveness of its methodologies. The company operates accredited labs in Austin, Texas, and San Carlos, California, as well as a lab in Boulder, Colorado, through its subsidiary Foresight Diagnostics.
Frequently Asked Questions (FAQ)
- What were Natera’s total revenues in the fourth quarter of 2025?
- Approximately $660 million, a 39% increase from $476 million in the same period of 2024.
- How many oncology tests did Natera process in Q4 2025?
- About 233,300 tests, marking a 55% year-over-year growth.
- What is the total number of tests processed by Natera in 2025?
- Approximately 3,525,500 tests, up 15% from 3,064,600 tests in 2024.
- How much did Natera’s cash inflows amount to in Q4 2025?
- Approximately $30 million, compared to $46 million in Q4 2024.
- When is Natera’s next earnings call scheduled?
- The complete fourth quarter and full year 2025 financial results will be released during its earnings call in February 2026.
FAQ Schema in JSON-LD Format
{
"@context": "https://schema.org",
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "What were Natera's total revenues in the fourth quarter of 2025?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Approximately $660 million, a 39% increase from $476 million in the same period of 2024."
}
},
{
"@type": "Question",
"name": "How many oncology tests did Natera process in Q4 2025?",
"acceptedAnswer": {
"@type": "Answer",
"text": "About 233,300 tests, marking a 55% year-over-year growth."
}
},
{
"@type": "Question",
"name": "What is the total number of tests processed by Natera in 2025?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Approximately 3,525,500 tests, up 15% from 3,064,600 tests in 2024."
}
},
{
"@type": "Question",
"name": "How much did Natera's cash inflows amount to in Q4 2025?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Approximately $30 million, compared to $46 million in Q4 2024."
}
},
{
"@type": "Question",
"name": "When is Natera's next earnings call scheduled?",
"acceptedAnswer": {
"@type": "Answer",
"text": "The complete fourth quarter and full year 2025 financial results will be released during its earnings call in February 2026."
}
}
]
}
Key Features of Natera’s 2025 Financial Performance
| Feature | Fourth Quarter 2025 | Full Year 2025 |
|---|---|---|
| Total Revenues | $660 million (39% increase from Q4 2024) | $2.3 billion (35% increase from 2024) |
| Oncology Tests Processed | 233,300 tests (55% year-over-year growth) | 800,800 tests (52% increase from 2024) |
| Clinical MRD Tests Processed | 225,300 tests (record sequential growth) | 769,700 tests (52% increase from 2024) |
| Total Tests Processed | 923,600 tests (17% increase from Q4 2024) | 3,525,500 tests (15% increase from 2024) |
| Cash Inflows | $30 million (compared to $46 million in Q4 2024) | Exceeding $100 million for the full year |
Deeper Dive: News & Info About This Topic
HERE Resources
Elon Musk’s xAI Acquires OpenAI: A Game-Changer for AI Sector
Author: STAFF HERE AUSTIN WRITER
The AUSTIN STAFF WRITER represents the experienced team at HEREAustinTX.com, your go-to source for actionable local news and information in Austin, Travis County, and beyond. Specializing in "news you can use," we cover essential topics like product reviews for personal and business needs, local business directories, politics, real estate trends, neighborhood insights, and state news affecting the area—with deep expertise drawn from years of dedicated reporting and strong community input, including local press releases and business updates. We deliver top reporting on high-value events such as SXSW, Austin City Limits Music Festival, Formula 1 United States Grand Prix, and the Austin Film Festival. Our coverage extends to key organizations like the Greater Austin Chamber of Commerce and Visit Austin, plus leading businesses in technology, automotive, and retail that power the local economy such as Dell Technologies, Tesla, and Apple. As part of the broader HERE network, including HERECollegeStation.com, HEREDallas.com, HEREHouston.com, and HERESanAntonio.com, we provide comprehensive, credible insights into Texas's dynamic landscape.
